Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer

Eur Urol. 2023 Jun;83(6):584-585. doi: 10.1016/j.eururo.2023.01.026. Epub 2023 Feb 11.

Authors

Timothée Olivier¹, Petros Tsantoulis², Vinay Prasad³

Affiliations

¹ Department of Oncology, Geneva University Hospital, Geneva, Switzerland. Electronic address: timothee.olivier@hcuge.ch.
² Department of Oncology, Geneva University Hospital, Geneva, Switzerland.
³ Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, CA, USA.

PMID: 36781336
DOI: 10.1016/j.eururo.2023.01.026

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Androgen Receptor Antagonists
Hormones
Humans
Male
Prostatic Neoplasms, Castration-Resistant* / pathology
Pyrazoles

Substances

darolutamide
Pyrazoles
Hormones
Androgen Receptor Antagonists